Synthaverse S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-12-13
Share capital
7,601,940.30 PLN
Activity description

Synthaverse is a Polish biotechnology company that has been operating since 1944, specializing in the development of immunotherapy solutions for various medical fields, including oncology, urology, gynecology, and tuberculosis treatment. The company offers products such as ONKO BCG, DAVOSTER, and DISTREPTAZA, aimed at supporting patients and the medical community.

Registered address
Uniwersytecka 10, 20-029 Lublin, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-72596-86698-BCSGS-29

Financials

Revenue history (in m)

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 245 days for 2023). All were audited by a statutory auditor.

  • 202506/07/2026
  • 202404/08/2025
  • 202317/03/2025
  • 202203/07/2023
  • 202128/07/2022
  • 202012/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 2.78
-0.06 (-2.29%)
2.702.752.802.852.7810:0012:0014:0016:00
Open
PLN 2.85
High
PLN 2.87
Low
PLN 2.71
Volume
94.59K
Avg. vol.
68.92K
Market cap
PLN 210.95M
P/E ratio
–
EPS
-PLN 0.28
Shares outstanding
76.02M
52-week
PLN 2.45 – 2.89
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 3.47mUSD -182.87kUSD -745.54k
Q1 2026USD 3.68mUSD -179.90kUSD -974.07k
Q4 2025USD 4.40mUSD -1.96mUSD -1.73m
Q3 2025USD 1.20mUSD -1.86mUSD -1.94m

Results for Q3 2026:Nov 30, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing3,883 / 24,548
Top 16%
City · Lublin177 / 4,827
Top 3.7%
Voivodeship · Lubelskie471 / 10,168
Top 4.6%
Country · Poland17,153 / 297,069
Top 5.8%

Results vs industry

Revenue
This companyUSD 11.56mMedianUSD 913.43kAverageUSD 25.82m
Net profit
This companyUSD -5.01mMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 14.01mMedianUSD 846.99kAverageUSD 21.42m
Assets
This companyUSD 76.38mMedianUSD 897.46kAverageUSD 31.52m

Offer

Certifications: GMP

Websites

Public procurement

3 tenders recorded as contractor, with a total value of $11,169.

SubjectAmount
Supply of chemical and diagnostic reagents and standards for Wojewódzka Stacja Sanitarno-Epidemiologiczna w Bydgoszczy
$1,465
Successive supply of chemical reagents and microbiological materials for Wojewódzka Stacja Sanitarno-Epidemiologiczna w Rzeszowie – procedure II
$8,410
Supply of laboratory and chemical reagents together with the lease of analysers and instruments – Lot No. 12: Supply of bacteriological media – Lowenstein-Jensen medium, drug resistance test kits
$1,294

Trademarks

The company holds 20 active trademarks registered with the Polish Patent Office. 5 marks have expired or were not registered. The first mark was filed in 1993.

MarkNumberClassesStatusProtected until
CINVIKLUD (word)Z.5767835Protected Nov 13, 2034
AMSUNEFIL (word)Z.5767735Protected Nov 13, 2034
SINRUDOLIF (word)Z.5767805Protected Nov 13, 2034
AVISTUAR (word)Z.5767815Protected Nov 13, 2034
FILCAZMIR (word)Z.5767825Protected Nov 13, 2034
MarkProtected until
CINVIKLUD (word)Nov 13, 2034
AMSUNEFIL (word)Nov 13, 2034
SINRUDOLIF (word)Nov 13, 2034
AVISTUAR (word)Nov 13, 2034
FILCAZMIR (word)Nov 13, 2034

Job offers

The company has its own careers page: synthaverse.com/pl/kariera.

Authorized Representatives

Artur Chodkowski age 51 – President of the Management Board
Dariusz Jan Kucowicz age 61 – Management Board Member
Jakub Tadeusz Winkler age 42 – Management Board Member
Paulina Otachel-Tymosiak age 34 – Attorney-in-fact (joint)

Manner of representation

For making declarations of will concerning the rights and obligations of the company and for signing on behalf of the company, the following are authorized: in the case of a one-person management board, the President independently, or two commercial proxies jointly. In the case of a multi-member management board: the President of the Management Board jointly with a member of the management board, or two members of the management board jointly, or a member of the management board jointly with a commercial proxy, or two commercial proxies jointly. Matters exceeding the ordinary management of the company require a resolution of the management board.

Supervisory board

Konrad Adam Miterski age 54 – Supervisory Board Member
Waldemar Artur Sierocki age 71 – Supervisory Board Member
Jarosław Paweł Błaszczak age 53 – Supervisory Board Member
Dirk Pamperin – Supervisory Board Member
Maciej Korniluk age 46 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2003-09-30.

Debt

1 closed proceeding recorded in KRZ history.

Registration dateProceeding typeStatus
Oct 25, 2024
Declaration of arrangement performance in restructuring
Closed

MSiG notices

36 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Oct 18, 2024Bankruptcy notice
Jul 24, 2024Bankruptcy notice
Apr 18, 2024Bankruptcy notice
Jan 17, 2024Bankruptcy notice
Oct 30, 2023Bankruptcy notice

Public aid

43 public aid cases recorded, with a total value of $24,963,309.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$5,048
De minimis aid (in accordance with Commission Regulation 2023/2831)
$3,952
De minimis aid (in accordance with Commission Regulation 2023/2831)
$2,009

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $18,006,964.

ProjectEU co-financing
Implementation of R&D results in the innovative technology for manufacturing a product for bladder cancer immunotherapy based on the Moreau substrain of attenuated BCG mycobacteria
$9.7M
Promotion of Onko BCG, a medicine used to treat superficial, epithelial, non-invasive bladder tumours, in foreign markets
$76,566
BCG Biotechnology Innovation Centre
$7.5M

Regulatory authorisations

AuthorityTypeStatus
Integrated permit Active

Competitors

Name
Biogen Poland sp. z o.o.
Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed S.A.
Biovico sp. z o.o.
Bio-Gen sp. z o.o.
Reig Jofre sp. z o.o.
Paso-Trading sp. z o.o.
Biofaktor sp. z o.o.
HAL Allergy sp. z o.o.
Fortis Pharmaceuticals sp. z o.o.
Celltrion Poland sp. z o.o.

Change history

DateEvent
2026-07-29Share capital increase
2025-11-19Share capital increase
2024-12-12Share capital increase
2024-02-14Share capital increase
2023-07-10Name change

FAQ

Last updated: 2026-10-03